Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial - Top-Institutions - MDSpire

Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial

  • By

  • Chloe Stanley

  • Ritwika Mallik

  • Nausheen Hamid

  • Friedrich C. Jassil

  • Victoria Reuven

  • Tapiwa Ruwona

  • Samuel J. Dicken

  • Sulmaaz Qamar

  • Benjamin Norton

  • Helen Kingett

  • Andrea Pucci

  • Cormac Magee

  • David Boniface

  • Rachel L. Batterham

  • Kalpana Devalia

  • Jessica Mok

  • Mohamed Elkalaawy

  • John Loy

  • Andrew Jenkinson

  • Haris Markakis

  • Marco Adamo

  • Alanna Brown

  • Janine Makaronidis

  • May 22, 2026

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Cleveland Clinic Bariatric & Metabolic Institute
    Cleveland Clinic Bariatric & Metabolic Institute

    Cleveland, Ohio

    Key Differentiators

    • Bariatric Surgery
    • Obesity Medicine

  • #2

    European Accreditation Council for Bariatric Surgery
    European Accreditation Council for Bariatric Surgery

    N/A, N/A

    Key Differentiators

    • Bariatric Surgery

  • #3

    Copenhagen University Hospital–Bispebjerg and Frederiksberg
    Copenhagen University Hospital–Bispebjerg and Frederiksberg

    Copenhagen, Denmark

    Key Differentiators

    • Obesity Medicine

  • #4

    Mental Health Centre Copenhagen
    Mental Health Centre Copenhagen

    Copenhagen, Denmark

    Key Differentiators

    • Obesity Medicine

  • #5

    Virginia Commonwealth University School of Medicine
    Virginia Commonwealth University School of Medicine

    Richmond, Virginia

    Key Differentiators

    • Obesity Medicine

Original Source(s)

Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial

  • by Chloe Stanley, Ritwika Mallik, Nausheen Hamid, Friedrich C. Jassil, Victoria Reuven, Tapiwa Ruwona, Samuel J. Dicken, Sulmaaz Qamar, Benjamin Norton, Helen Kingett, Andrea Pucci, Cormac Magee, David Boniface, Rachel L. Batterham, Kalpana Devalia, Jessica Mok, Mohamed Elkalaawy, John Loy, Andrew Jenkinson, Haris Markakis, Marco Adamo, Alanna Brown, Janine Makaronidis

  • May 22, 2026

Related Content

Comparison of the association and discriminatory ability of CVAI, LAP, CI, and AVI for type 2 diabetes in Chinese adults aged ≥ 50 years: a sex-specific analysis

The immunometabolic mechanisms and therapeutic targets of metabolic dysfunction-associated steatohepatitis

Lipidomics Point to Obesity–Alzheimer's Link

Study uses multi-omics tools to examine obesity-related pathways linked to neurodegeneration

  • May 26, 2026

  • 2 min